These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7398733)

  • 1. Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol.
    Leahey WJ; Neill JD; Varma MP; Shanks RG
    Eur J Clin Pharmacol; 1980 Jun; 17(6):419-24. PubMed ID: 7398733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Observations on some properties of a long-acting preparation of propranolol.
    Shanks RG; Neill JD; Leahey WJ; Varma MP
    Clin Sci (Lond); 1979 Dec; 57 Suppl 5():409s-411s. PubMed ID: 540460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the beta-adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation.
    Kerr MJ; Harron DW; Kinney C; Shanks RG
    Br J Clin Pharmacol; 1981 Dec; 12(6):869-71. PubMed ID: 6122463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade.
    McDevitt DG; Brown HC; Carruthers SG; Shanks RG
    Clin Pharmacol Ther; 1977 May; 21(5):556-66. PubMed ID: 15753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-dosing plasma concentrations and beta-adrenoceptor blocking effects during repeated once daily dosing with 160 mg sustained-release propranolol (Inderal LA) and 16/260 oxprenolol Oros to healthy volunteers.
    Moppert J; Degen PH; Racine-Poon A
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):197S-201S. PubMed ID: 2988591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects.
    West MJ; Kendall MJ; Mitchard M; Faragher EB
    Br J Clin Pharmacol; 1976 Jun; 3(3):439-43. PubMed ID: 788749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observations on the efficacy and pharmacokinetics of sotalol after oral administration.
    Brown HC; Carruthers SG; Kelly JG; McDevitt DG; Shanks RG
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):367-72. PubMed ID: 971701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the duration of action of pindolol and slow release oxprenolol in healthy volunteers.
    Aellig WH
    Eur J Clin Pharmacol; 1978 Nov; 14(3):167-9. PubMed ID: 729611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise.
    Bobik A; Jennings GL; Korner PI; Ashley P; Jackman G
    Br J Clin Pharmacol; 1979 Jun; 7(6):545-9. PubMed ID: 465276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers.
    Bennett PN; Bennett J; Bradbrook I; Francis J; John VA; Rogers H; Turner P; Warrington SJ
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):171S-175S. PubMed ID: 4005119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug.
    Balnave K; Neill JD; Russell CJ; Harron DW; Leahey WJ; Wilson R; Shanks RG
    Br J Clin Pharmacol; 1981 Feb; 11(2):171-80. PubMed ID: 6111331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concentration-effect relationship of oxprenolol in healthy volunteers: a retrospective analysis.
    Racine-Poon A; Moppert J
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):143S-149S. PubMed ID: 4005116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of oxprenolol in normal subjects.
    Mason WD; Winer N
    Clin Pharmacol Ther; 1976 Oct; 20(4):401-12. PubMed ID: 10124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers.
    Woods KL; Jack DB; Kendall MJ; Halsey A; O'Donnell ML; Warrington SJ; John VA
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):177S-184S. PubMed ID: 4005120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical effects of propranolol (Inderal) with once daily slow-release oxprenolol (Slow Trasicor) in angina pectoris.
    Majid PA; de Feijter PJ; Wardeh R; van der Wall EE; Roos JP
    J Int Med Res; 1979; 7(3):194-200. PubMed ID: 378729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of -blocking drugs on atrioventricular conduction and contractility.
    Fitzgerald JD; Wale J
    Cardiology; 1971; 56(1):338-43. PubMed ID: 4403201
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of beta-adrenoceptor blocking properties of sotalol, oxprenolol, propranolol and pindolol on rabbit intestinal smooth muscle.
    Salimi M
    Pharmacology; 1975; 13(5):441-7. PubMed ID: 1802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies with long acting propranolol.
    Shanks RG
    Postgrad Med J; 1984; 60 Suppl 2():61-8. PubMed ID: 6463010
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of beta-adrenergic blocking activities of propranolol, isopropylmethoxamine, sotalol, practolol, alprenolol, pindolol, oxprenolol and D-32 in the atria and trachea of the guinea-pig.
    Horii D; Kawada T; Takeda K; Imai S
    Arzneimittelforschung; 1974 Sep; 24(9):1275-7. PubMed ID: 4154764
    [No Abstract]   [Full Text] [Related]  

  • 20. Twenty-four hour effects of oxprenolol Oros and atenolol on heart rate, blood pressure, exercise tolerance and perceived exertion.
    van Baak MA; Verstappen FT; Oosterhuis B
    Eur J Clin Pharmacol; 1986; 30(4):399-406. PubMed ID: 3743615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.